Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 46, 2009, Pages 19485-19490

  Lee, Samantha Lin Chiou ^a,b   Rouhi, Pegah ^a   Jensen, Lasse Dahl ^a   Zhang, Danfang ^a   Ji, Hong ^a   Hauptmann, Giselbert ^a,c   Ingham, Philip ^b   Cao, Yihai ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^c School of Life Sciences Södertörn University   (Sweden)

Author keywords

Hypoxia; Tumor invasion; VEGF

Indexed keywords

MORPHOLINE DERIVATIVE; OLIGONUCLEOTIDE; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2; ENHANCED GREEN FLUORESCENT PROTEIN; GREEN FLUORESCENT PROTEIN; TRANSCRIPTION FACTOR FLI 1; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INVASION; CELL INVASION; CONTROLLED STUDY; FIBROSARCOMA; HUMAN; HUMAN TISSUE; HYPOXIA; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; ZEBRA FISH; ANIMAL; CELL HYPOXIA; DISEASE MODEL; DRUG ANTAGONISM; GENETICS; METABOLISM; MOUSE; PATHOLOGY; TRANSGENIC ANIMAL; TUMOR CELL LINE;

DANIO RERIO; MURINAE;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CELL HYPOXIA; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GREEN FLUORESCENT PROTEINS; HUMANS; MICE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEIN C-FLI-1; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; ZEBRAFISH;

EID: 73349090963     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0909228106     Document Type: Article

References (43)

1. Folkman J (1971) Tumor angiogenesis: Therapeutic implications. N Engl J Med 285:1182-1186.
2. Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324:1-8.
3. Cao Y (2009) Tumor angiogenesis and molecular targets for therapy. Front Biosci 14:3962-3973.
4. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249-257.
5. Jain RK (2005) Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307:58-62.
6. Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358:2039-2049.
7. Heldin CH, Rubin K, Pietras K, Ostman A (2004) High interstitial fluid pressure-an obstacle in cancer therapy. Nat Rev Cancer 4:806-813.
8. Bhandarkar SS, et al. (2009) Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice. J Clin Invest 119:2359-2365.
9. Blagosklonny MV (2004) Antiangiogenic therapy and tumor progression. Cancer Cell 5:13-17.
10. Du R, et al. (2008) HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13:206-220.
11. Erler JT, et al. (2009) Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15:35-44.
12. Nikolopoulos SN, Blaikie P, Yoshioka T, Guo W, Giancotti FG (2004) Integrin beta4 signaling promotes tumor angiogenesis. Cancer Cell 6:471-483.
13. Wei J, et al. (2004) Embryonic endothelial progenitor cells armed with a suicide gene target hypoxic lung metastases after intravenous delivery. Cancer Cell 5:477-488.
14. Kerbel RS (2006) Antiangiogenic therapy: A universal chemosensitization strategy for cancer? Science 312:1171-1175.
15. Paez-Ribes M, et al. (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220-231.
16. Ebos JM, et al. (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15:232-239.
17. Pantel K, Brakenhoff RH (2004) Dissecting the metastatic cascade. Nat Rev Cancer 4:448-456.
18. Boutin AT, et al. (2008) Epidermal sensing of oxygen is essential for systemic hypoxic response. Cell 133:223-234.
19. Mandriota SJ, et al. (2002) HIF activation identifies early lesions in VHL kidneys: Evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1:459-468.
20. Bruick RK, McKnight SL (2001) A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294:1337-1340.
21. Semenza GL (2001) HIF-1, O(2), and the 3 PHDs: How animal cells signal hypoxia to the nucleus. Cell 107:1-3.
22. Lawson ND, Weinstein BM (2002) In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev Biol 248:307-318.
23. Miao J, et al. (2007) HOXB13 promotes ovarian cancer progression. Proc Natl Acad Sci USA 104:17093-17098.
24. Yin JJ, et al. (1999) TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103:197-206.
25. Eriksson A, et al. (2002) Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. Cancer Cell 1:99-108.
26. Xue Y, et al. (2008) Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome. Proc Natl Acad Sci USA 105:18513-18518.
27. Billemont B, Barete S, Rixe O (2008) Scrotal cutaneous side effects of sunitinib. N Engl J Med 359:975-976.
28. Motzer RJ, et al. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124.
29. Rottbauer W, et al. (2005) VEGF-PLCgamma1 pathway controls cardiac contractility in the embryonic heart. Genes Dev 19:1624-1634.
30. Nicoli S, Presta M (2007) The zebrafish/tumor xenograft angiogenesis assay. Nat Protoc 2:2918-2923.
31. Lee P, et al. (2002) Neuropilin-1 is required for vascular development and is a mediator of VEGF-dependent angiogenesis in zebrafish. Proc Natl Acad Sci USA 99:10470-10475.
32. Carmeliet P, et al. (1996) Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380:435-439.
33. Ferrara N, et al. (1996) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380:439-442.
34. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70.
35. Husemann Y, et al. (2008) Systemic spread is an early step in breast cancer. Cancer Cell 13:58-68.
36. Aguirre-Ghiso JA (2007) Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7:834-846.
37. Adorno M, et al. (2009) A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 137:87-98.
38. Cao R, Jensen LD, Soll I, Hauptmann G, Cao Y (2008) Hypoxia-induced retinal angiogenesis in zebrafish as a model to study retinopathy. PLoS ONE 3:e2748.
39. Nasevicius A, Ekker SC (2000) Effective targeted gene 'knockdown' in zebrafish. Nat Genet 26:216-220.
40. Holmquist-Mengelbier L, et al. (2006) Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell 10:413-423.
41. Bose P, Holter JL, Selby GB (2009) Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 360:2143-2144.
42. Haines IE, Miklos GL (2008) Paclitaxel plus bevacizumab for metastatic breast cancer. N Engl J Med 358:1637-1638.
43. Sculier JP, Meert AP, Paesmans M (2007) Bevacizumab for non-small-cell lung cancer. N Engl J Med 356:1373-1374.